Financial Lp Hrt Acquires 3,959 Shares of Shuttle Pharmaceuticals (NASDAQ:SHPH) Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt acquired 3,959 shares of the firm’s stock in a transaction on Wednesday, July 1st. The shares were bought at an average cost of $3.30 per share, for a total transaction of $13,064.70. Following the completion of the acquisition, the insider directly owned 82,556 shares of the company’s stock, valued at approximately $272,434.80. This represents a 5.04% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Tuesday, June 30th, Financial Lp Hrt acquired 6,755 shares of Shuttle Pharmaceuticals stock. The stock was bought at an average price of $3.23 per share, for a total transaction of $21,818.65.
• On Monday, June 29th, Financial Lp Hrt bought 25,836 shares of Shuttle Pharmaceuticals stock. The stock was bought at an average cost of $3.44 per share, with a total value of $88,875.84.

Shuttle Pharmaceuticals Stock Performance

Shares of NASDAQ SHPH traded up $0.03 during midday trading on Thursday, reaching $3.43. 160,775 shares of the company traded hands, compared to its average volume of 550,761. The firm has a market cap of $2.20 million, a PE ratio of -0.07 and a beta of 0.29. Shuttle Pharmaceuticals Holdings, Inc. has a 12 month low of $2.90 and a 12 month high of $55.90. The stock’s 50-day simple moving average is $5.93 and its 200-day simple moving average is $10.74.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last posted its earnings results on Tuesday, March 31st. The company reported $0.60 earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Shuttle Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in SHPH. Ikarian Capital LLC acquired a new position in shares of Shuttle Pharmaceuticals during the fourth quarter valued at $124,000. Boothbay Fund Management LLC bought a new stake in Shuttle Pharmaceuticals during the 4th quarter worth about $37,000. Geode Capital Management LLC bought a new stake in Shuttle Pharmaceuticals during the 4th quarter worth about $26,000. Finally, Connective Capital Management LLC acquired a new position in Shuttle Pharmaceuticals during the 3rd quarter valued at about $357,000. 4.58% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .